Dectomax CA-1
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The USDA, Animal and Plant Health Inspection Service (APHIS), intends to award a sole source supply contract to Zoetis US, LLC for a one-time purchase of Dectomax CA-1 injectable. This product is crucial for the treatment and prevention of New World Screwworm (NWS) in cattle. This is not a request for competitive proposals, but interested sources, including small businesses, are encouraged to provide detailed capability information by March 23, 2026.
Scope of Work
This opportunity is for the one-time purchase of Dectomax CA-1 injectable to treat and prevent New World Screwworm (NWS) myiasis in cattle. The USDA is prioritizing readiness for a potential NWS incursion due to its significant threat to animal and public health, and the U.S. economy. Dectomax CA-1 is conditionally approved by the FDA as an injectable prevention and treatment for NWS larval infestations.
Contract & Timeline
- Type: Sole Source, Firm-Fixed Price (FFP) supply contract under FAR 6.302-1.
- Vendor: Zoetis US, LLC (Unique entity ID MXRTXKG318E5).
- Set-Aside: None (sole source justification).
- NAICS Code: 325414 (Drugs And Biologicals).
- Response Due: March 23, 2026, 1:00 PM ET.
- Published: February 24, 2026.
Evaluation
This is not a request for competitive proposals. The government's determination not to compete this requirement will be based on responses received from interested sources. Information provided is strictly voluntary and will not result in a contract award or reimbursement for participants. The requirement is essential to meeting government needs.
Additional Notes
Zoetis is identified as the only known manufacturer of Dectomax CA-1, which is the sole FDA conditionally approved injectable product for this purpose in cattle. The product is not yet commercially available to the public, presenting a unique opportunity for USDA to acquire it. The justification cites "unusual and compelling urgency" due to the NWS threat. Market research confirms no other conditionally approved injectable macrocytic lactone medication exists for this use, and the product is not available from other distributors.